Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vamikibart - Roche

Next Previous
Drug Profile

Vamikibart - Roche

Alternative Names: RG-6179; RO-7200220

Latest Information Update: 19 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Anti-inflammatories; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Retinal oedema
  • Phase II Diabetic macular oedema

Most Recent Events

  • 21 Apr 2025 Hoffmann-La Roche completes a phase II trial in Diabetic macular oedema in United Kingdom, Spain, Puerto Rico, Poland, South Korea, Czech Republic, Canada, Argentina, USA (Intravitreous) (NCT05151731)
  • 01 Oct 2024 Hoffmann-La Roche completed a phase II trial in Diabetic macular oedema (Combination therapy) in the US, South Korea, the UK, Spain, Puerto Rico, Poland, Israel, Canada, Argentina (Intravitreous, Injection) (NCT05151744)
  • 09 May 2024 Roche plans to file regulatory filing for Diabetic macular oedema, in or after 2027 (Roche pipeline, May 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top